---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-021769"
form_type: "8-K"
ticker: "CLSDQ"
cik: "0001539029"
company_name: "Clearside Biomedical, Inc."
filed_at: "2023-05-12T23:59:59+00:00"
generated_at: "2026-06-15T02:29:18.354653+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Clearside terminates Cowen ATM facility, enters new up to $50M at-the-market equity deal with Cantor

## Summary
- Terminated prior Cowen Sales Agreement effective May 12, 2023; $35.8M net raised from ~19M shares since 2017.
- Entered new Controlled Equity Offering with Cantor Fitzgerald to sell up to $50M of common stock at-the-market.
- Cantor will receive up to 3% commission on gross sales; Company not obligated to sell any shares.
- New facility provides ongoing equity capital access for the biotech firm.

## SEC filing metadata
- accession: 0000950170-23-021769
- form_type: 8-K
- ticker: CLSDQ
- cik: 0001539029
- company_name: Clearside Biomedical, Inc.
- filed_at: 2023-05-12T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 1.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1539029/000095017023021769/0000950170-23-021769-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1539029/000095017023021769/clsd-20230512.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-021769
- JSON: https://secwatch.observer/filing/0000950170-23-021769.json
- Plain text: https://secwatch.observer/filing/0000950170-23-021769.txt

## Key facts
- Material Agreements
  Clearside Biomedical, Inc. entered into Controlled Equity Offering Sales Agreement with Cantor Fitzgerald & Co. valued at $50 million (effective 2023-05-12).
  - Action: entry
  - Agreement: atm program
  - Counterparty: Cantor Fitzgerald & Co.
  - Value: $50 million
  - Effective: 2023-05-12
  source text: On May 12, 2023, Clearside Biomedical, Inc. (the “ Company ”) entered into a Controlled Equity Offering SM Sales Agreement (the “ Agreement ”) with Cantor Fitzgerald & Co. (“ Cantor ”) under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, par value $0.001 per share (the “ Common Stock ”), having an aggregate offering price of up to $50 million through or to Cantor as its sales agent or principal.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1539029/000095017023021769/0000950170-23-021769-index.htm
- Material Agreements
  Clearside Biomedical, Inc. terminated Sales Agreement dated June 30, 2017 with Cowen and Company, LLC with Cowen and Company, LLC valued at terminated (effective 2023-05-12).
  - Action: termination
  - Agreement: atm program
  - Counterparty: Cowen and Company, LLC
  - Value: terminated
  - Effective: 2023-05-12
  source text: On May 12, 2023, the Company and Cowen and Company, LLC (“ Cowen ”) agreed to terminate the Sales Agreement, dated as of June 30, 2017, (the “ Prior Sales Agreement ”) between the Company and Cowen, effective as of May 12, 2023 (the “ Termination Date ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1539029/000095017023021769/0000950170-23-021769-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.